Compare AIN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | NEO |
|---|---|---|
| Founded | 1895 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1994 | 2008 |
| Metric | AIN | NEO |
|---|---|---|
| Price | $61.10 | $19.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $60.25 | $13.38 |
| AVG Volume (30 Days) | 212.4K | ★ 1.9M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,054,132,000.00 | N/A |
| Revenue This Year | $1.20 | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $53.19 | ★ N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $41.15 | $7.07 |
| 52 Week High | $77.00 | $20.05 |
| Indicator | AIN | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 61.61 |
| Support Level | $58.66 | $16.87 |
| Resistance Level | $64.30 | $19.76 |
| Average True Range (ATR) | 1.72 | 0.83 |
| MACD | 0.43 | -0.00 |
| Stochastic Oscillator | 58.42 | 78.03 |
Albany International Corp is a textiles and materials processing company specializing in engineered fabrics and composite components and assemblies for the paper, industrial manufacturing and aerospace industries. It operates through two segments: Machine Clothing, which produces custom-designed fabrics and high-speed process belts for paper, paperboard, tissue, towel and pulp, as well as engineered fabrics for other industrial applications, and contributes the majority of revenue; and Albany Engineered Composites, which provides engineered composite parts for the aerospace and defense industries. The company generates revenue from the United States, Switzerland, Brazil, China, Mexico, France and other areas.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.